AstraZeneca presents new data on Faslodex in breast cancer and provides immuno-oncology update at ESMO 2016 congress

Click here to view online. Add this email to your safelist.

30 September 2016

AstraZeneca, along with its global biologics research and development arm, MedImmune, will showcase the growing potential of its broad portfolio of cancer medicines through 46 scientific presentations, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, from 7-11 October 2016.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.